Capital Research Global Investors Acquires New Position in Sanofi $SNY

Capital Research Global Investors acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,650,018 shares of the company’s stock, valued at approximately $79,960,000.

Several other large investors have also bought and sold shares of the company. Flagship Harbor Advisors LLC bought a new position in shares of Sanofi in the fourth quarter worth approximately $25,000. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the third quarter valued at approximately $29,000. Palisade Asset Management LLC purchased a new position in Sanofi in the 3rd quarter worth approximately $30,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in Sanofi by 544.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock valued at $34,000 after acquiring an additional 588 shares in the last quarter. Finally, Larson Financial Group LLC lifted its position in Sanofi by 48.9% in the 4th quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock valued at $39,000 after acquiring an additional 266 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Trading Down 2.5%

NASDAQ:SNY opened at $43.88 on Tuesday. The company has a market cap of $106.38 billion, a PE ratio of 12.26, a price-to-earnings-growth ratio of 1.11 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The company has a 50 day simple moving average of $45.40 and a two-hundred day simple moving average of $46.67. Sanofi has a 12 month low of $42.28 and a 12 month high of $52.68.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a $2.4225 dividend. The ex-dividend date of this dividend was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. Sanofi’s dividend payout ratio is presently 49.16%.

Wall Street Analyst Weigh In

SNY has been the subject of a number of research analyst reports. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research report on Monday, April 20th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Finally, Citigroup reissued a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.